Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer Cells
Open Access
- 1 January 2008
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 283 (2), 739-750
- https://doi.org/10.1074/jbc.m706287200
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- AKT/PKB Signaling: Navigating DownstreamCell, 2007
- MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cellsJournal of Cellular Physiology, 2007
- Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 BindingMolecular and Cellular Biology, 2006
- Scaffolding Protein Grb2-associated Binder 1 Sustains Epidermal Growth Factor-induced Mitogenic and Survival Signaling by Multiple Positive Feedback LoopsPublished by Elsevier BV ,2006
- Akt/PKB Signaling in Cancer: A Function in Cell Motility and InvasionCell Cycle, 2006
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- A comprehensive pathway map of epidermal growth factor receptor signalingMolecular Systems Biology, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Expression of amphiregulin and epidermal growth factor receptor in human breast cancer: analysis of autocriny and stromal-epithelial interactionsThe Journal of Pathology, 2001
- Treatment of Breast CancerNew England Journal of Medicine, 1998